Veeda™ Lifesciences

Veeda Group: Integrated, Tech-Driven, Global CRO

Our Support Spans the Entire Spectrum of Drug Development Phases



- Discovery
- Chemistry
- Bioanalysis
- Toxicology

- Phase I
- Phase II
- Bioequivalence Studies (Healthy & Patient)

- Phase III
- Pharmacovigilance (PV) / Real World Evidence (RWE)

- Small Molecule
- Biologics
- Biosimilars

Preclinical Capabilities: A Foundation for Success

Generics Preclinical

- Impurity qualification (Ames test, Enhanced Ames, In vitro CAT, systemic tox)
- ANDA/NDA, 505(B)2 toxicity studies
- Analytical & Bioanalytical MD, MV & analysis
- Nonclinical Biodistribution studies (Complex injectables - FCM, Iron sucrose & liposomal drugs)
- Environmental risk assessment (ERA): Tier based, Phys-chem, Ecotoxicology

300+ impurity qualification studies

Innovators (NCE/Small molecules)

- DMPK/ Standalone PK
- IND enabling studies
- Inhalation Toxicity
- Genetic toxicity
- DART/Reprotox

Team of 450+ scientists

Biopharma Preclinical

- Safety / Toxicity with Immunogenicity assessment
- Custom HCP assay dev., mAbs, pAbs generation
- Biological assays

23,500+ GLP studies

Synthetic, Chemistry Services

- Medicinal chemistry, Custom Synthesis, Process R&D and scale up
- Synthesis of novel scaffolds, building blocks & NCEs
- Isolation, Characterization, Identification & Synthesis of Impurities

One of the Largest Vivarium in the Country with 115 animal rooms

Comprehensive Bioequivalence Expertise: Supporting Healthy Volunteer Studies

- Expertise in Healthy Volunteer Bioequivalence (BE) Studies; Specialization in Complex Generics & Biosimilars
- 4,900+ Successfully Completed Healthy Volunteer Studies
- 85,000+ Volunteer Database

Early Phase Trial Capabilities: Extensive Assistance for a Diverse Range of Complex Drug Products

- Phase I First-in-Human, Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) & Proof of Concept Studies for New Chemical Entities (NCEs)
  - 588 Beds & 22 Special Beds Across 16 Clinics
  - 30 Intensively Monitored Beds for Phase I / First-in-Human Studies

Partnered with 19 Unique Sponsors for Phase I Studies Globally

Enhancing the Potential of Your Complex Generic Portfolio with our Comprehensive Capabilities

Experience in Handling **230+** Complex Generic Studies

Leaders in Injectable Research: Including 18 Long-Acting Formulations



- Glucose Clamp Studies
- Phase I Studies
- Suppositories Studies
- Patches Studies
- Injectable Studies
- Inhalation Studies
- Studies via 505(b)(2) Pathway

Precision and Compliance in Clinical Trials: From Design to Delivery

Clinical Studies Execution across 26 Geographies; US, EU, and Asia-Pacific Regions

- Expertise in Patient Bioequivalence (BE) Studies; Clinical End Point & Pharmacokinetic (PK) Studies
- Innovator Drug Development Trials; Phase I to Phase III Trials for New Chemical Entities (NCEs) & Novel Biologic Entities (NBEs)
- Phase III Biosimilar Trials; Advancing Biosimilar through Phase III trials, evaluating Safety, Efficacy, and Immunogenicity
- Phase I/III Integrated Studies for Oncology Biosimilars
- Phase IV Studies; PMS Studies & Pharmacovigilance services

Leading CRO supporting the fight against Multiple Myeloma

10,000+
Patient Database

750+
Sites

1800+
Investigator Database

20+
Ongoing Phase I-IV Trials

55+ Patient
Bioequivalence Studies

40+ Oncology trials

Regulatory Excellence: 27 USFDA & 2 EMA Inspections with Zero 483 Observations

Leveraging e-Clinical Platforms to Accelerate Trials



Advanced Bioanalytical Expertise: Method Development, Validation and Sample Analysis

Over **1240+** bioanalytical methods with an average runtime of under 5 minutes, covering diverse categories.

1008 + 21	Generics + Pharmacodynamics/ Immunogenicity
112	Complex Generics
101	NCEs

Laboratory Infrastructure

- LC-MS/MS, ICP-OES, ICP-MS, LHS & LIMS machines
- BSL class-2 lab for Infectious Samples
- Deep Freezers and Cold Room for Plasma Samples
- Pharma Refrigerators, Walk-In & Humidity Chambers

Timeliness & Technical Expertise

- Uniquely Positioned to rapidly advance NCE development using SFC-MS/MS
- Capable of Processing 1,20,000 samples per month
- Complex molecule method development <3weeks
- Sample analysis, within 5 days to support FIH study for NCE dose escalation studies.
- >240 Trained and competent scientific team to handle regulated bioanalysis.
- ISR acceptance > 97%

Veeda Biopharma: Customized Integrated Solutions across Different Modalities

We specialize in catering to the diverse R&D requirements of global biopharmaceutical & biotechnology clients across a wide array of modalities.



One-Stop Solution for Novel Therapeutics and Biosimilars



High-resolution separation of complex mixtures based on charge-to-mass ratios through exclusive ZIPCHIP technology

Center of Excellence for Analytics & Characterization, including Rapid N-Glycan Analysis within 3-4 Days

145 Successful Regulatory Audits to Date

+91 79677 73000
info@veedalifesciences.com
www.veedalifesciences.com

Excellence In Everything